Commonwealth Biotechnologies, Inc. (CBI) expanded its operations into Japan through Venturepharm (Asia), with the opening of a new Tokyo office The new office will focus on supplying business development and localized customer service to the Japanese pharmaceutical and biotechnology industry.
"This new office, our first in Japan, marks CBI's growth into one of the major world markets for pharmaceutical and biotechnology R&D," said Paul D'Sylva, Chief Executive Officer of CBI, in a press release.
"Adding this office allows us to offer our Japanese customers the added benefit of expert local client support and project management from one of the premier contract discovery research services organizations in the world, providing compound screening, medicinal, computational and synthetic chemistry capabilities and related bioanalytical services."
The company also appointed of Mikio Taniguchi as regional business development manager for the region. "Mikio Taniguchi has a strong background in both business and medicinal chemistry, having both conducted research at some of Japan's largest pharmaceutical companies and worked in the venture capital and investment banking sectors focused on the pharmaceutical and biotechnology industry. He will be responsible for providing business development and client support for CBI products and services related to drug discovery collaborations, and the products and services of our Exelgen, Mimotopes, and CBI business units," Dr D'Sylva added.
Commonwealth Biotechnologies, Inc. (CBI) is a dynamic contract research organization and a partner to the global life sciences industry, offering a comprehensive, integrated range of services for the discovery and development of therapeutics, vaccines and diagnostic products. With the insight, innovation and project management skills that come from extensive experience, CBI offers its customers exceptional value whether they are a pharmaceutical giant or an emerging biotechnology company.
CBI operates five distinct business units: (1) CBI Services, a discovery-phase contract research organization; (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes Pty Ltd, Melbourne, Australia, a peptide and discovery chemistry business; (4) Exelgen Ltd, Bude, UK, a medicinal and synthetic discovery chemistry business; and (5) Venturepharm Asia, Beijing, China, a contract research business unit specializing in process scale-up, formulation development, cGMP manufacturing and clinical trial management.